WO2009084041A3 - Pharmaceutical compositions of dexibuprofen - Google Patents

Pharmaceutical compositions of dexibuprofen Download PDF

Info

Publication number
WO2009084041A3
WO2009084041A3 PCT/IN2008/000876 IN2008000876W WO2009084041A3 WO 2009084041 A3 WO2009084041 A3 WO 2009084041A3 IN 2008000876 W IN2008000876 W IN 2008000876W WO 2009084041 A3 WO2009084041 A3 WO 2009084041A3
Authority
WO
WIPO (PCT)
Prior art keywords
dexibuprofen
pharmaceutical compositions
active ingredient
vitro dissolution
importantly
Prior art date
Application number
PCT/IN2008/000876
Other languages
French (fr)
Other versions
WO2009084041A4 (en
WO2009084041A2 (en
Inventor
Milind Kesharlal Biyani
Vivekanandan Sundaramurthy
Devarajan Sampath Kumar
Original Assignee
Shasun Chemicals And Drugs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shasun Chemicals And Drugs Limited filed Critical Shasun Chemicals And Drugs Limited
Publication of WO2009084041A2 publication Critical patent/WO2009084041A2/en
Publication of WO2009084041A3 publication Critical patent/WO2009084041A3/en
Publication of WO2009084041A4 publication Critical patent/WO2009084041A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Abstract

The present invention relates to formulations of pharmaceutical compositions and in particular to a process of manufacture of such pharmaceutical compositions comprising dexibuprofen and/or salts in oral dosage form possessing high in-vitro dissolution and enhanced bioavailability in humans. Importantly, the invention is directed to high in-vitro dissolution of a poor water soluble drug dexibuprofen by controlling the particle size of the active ingredient of the invention such as dexibuprofen, to enable a significant improvement in the in-vivo performance of the active ingredient.
PCT/IN2008/000876 2008-01-01 2008-12-31 Pharmaceutical compositions of dexibuprofen WO2009084041A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1CH2008 2008-01-01
IN1/CHE/2008 2008-01-01

Publications (3)

Publication Number Publication Date
WO2009084041A2 WO2009084041A2 (en) 2009-07-09
WO2009084041A3 true WO2009084041A3 (en) 2009-10-29
WO2009084041A4 WO2009084041A4 (en) 2009-12-23

Family

ID=40824854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000876 WO2009084041A2 (en) 2008-01-01 2008-12-31 Pharmaceutical compositions of dexibuprofen

Country Status (1)

Country Link
WO (1) WO2009084041A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101829064B (en) * 2010-04-27 2012-04-25 海南新中正制药有限公司 Dexibuprofen particle and preparation method thereof
WO2013154512A1 (en) * 2012-04-13 2013-10-17 Mahmut Bilgic Pharmaceutical formulations comprising dexibuprofen
CN104546732A (en) * 2013-10-24 2015-04-29 北京韩美药品有限公司 Dexibuprofen sustained-release tablet and preparation process thereof
CN111135146A (en) * 2018-11-05 2020-05-12 珠海润都制药股份有限公司 Ibuprofen sustained-release pellet and preparation method thereof
GB2581132B (en) * 2019-01-28 2022-06-01 Reckitt Benckiser Health Ltd Novel composition
CN110327309B (en) * 2019-07-17 2023-02-10 珠海润都制药股份有限公司 Ibuprofen sustained-release pellet without pill sticking

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032896A2 (en) * 2001-10-18 2003-04-24 Strides Arcolab Limited Dexibuprofen-containing soft gelatin capsules and process for preparing the same
US20030170194A1 (en) * 2000-05-19 2003-09-11 Ralf Piotrowiak Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid
US20050147668A1 (en) * 1998-09-10 2005-07-07 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
US20060039981A1 (en) * 2002-09-04 2006-02-23 Deepak Murpani Taste masked dosage forms and processes for their preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050147668A1 (en) * 1998-09-10 2005-07-07 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
US20030170194A1 (en) * 2000-05-19 2003-09-11 Ralf Piotrowiak Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid
WO2003032896A2 (en) * 2001-10-18 2003-04-24 Strides Arcolab Limited Dexibuprofen-containing soft gelatin capsules and process for preparing the same
US20060039981A1 (en) * 2002-09-04 2006-02-23 Deepak Murpani Taste masked dosage forms and processes for their preparation

Also Published As

Publication number Publication date
WO2009084041A4 (en) 2009-12-23
WO2009084041A2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2015120110A3 (en) Novel pharmaceutical formulations
EP3626253A3 (en) Stable formulations of linaclotide
WO2012020097A3 (en) Use of binders for manufacturing storage stable formulations
HK1111609A1 (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2011107970A3 (en) Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect.
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
UA96622C2 (en) Solid dosage forms comprising aliskiren obtained by solvent-free granulation process
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2008093075A3 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
WO2010026467A3 (en) Controlled release tablet of a highly water soluble active agent such as levetiracetam, or citicoline
WO2010080754A3 (en) Nanoparticle pharmaceutical formulations
EP2196463A4 (en) Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08868986

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08868986

Country of ref document: EP

Kind code of ref document: A2